365:
ISIS-3 (Third
International Study of lnfarct Survival) Collaborative Group (1992), "ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction",
414:
ISIS-4 (Fourth
International Study of Infarct Survival) Collaborative Group (1995), "ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction",
308:
ISIS-2 (Second
International Study of lnfarct Survival) Collaborative Group (1988), "Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2",
260:
ISIS-1 (Second
International Study of lnfarct Survival) Collaborative Group (1986), "Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1",
449:
400:
351:
294:
469:
42:("heart attack"). More than 134,000 patients from over 20 countries took part in four large simple trials between 1981 and 1993, coordinated from
175:
474:
181:
244:
201:
Hennekens, Charles H. (1998), "Trials of
Thrombolytic Therapy: the International Studies of Infarct Survival Experience",
141:
110:
28:
55:
153:
39:
137:
98:
74:
227:
Hennekens, Charles H.; Skerrett, P.J. (2005). "International
Studies of Infarct Survival (ISIS)".
432:
383:
334:
277:
157:
443:
394:
345:
326:
288:
240:
424:
375:
318:
269:
232:
210:
36:
214:
428:
322:
273:
463:
379:
145:
118:
106:
86:
436:
338:
114:
102:
82:
59:
387:
281:
236:
149:
330:
62:
136:
The Fourth
International Study of Infarct Survival (ISIS-4) was a 2×2×2
125:
121:
78:
73:
The Second
International Study of Infarct Survival (ISIS-2) was a 2×2
97:
The Third
International Study of Infarct Survival (ISIS-3) was a 3×2
43:
172:, an Italian group who conducted four similar large clinical trials
169:
54:
32:
160:. It recruited 58,050 patients and was completed in 1993.
128:. It recruited 41,299 patients and was completed in 1991.
89:. It recruited 17,187 patients and was completed in 1988.
65:. It recruited 16,027 patients and was completed in 1985.
8:
124:to no heparin. All patients were also given
448:: CS1 maint: numeric names: authors list (
399:: CS1 maint: numeric names: authors list (
350:: CS1 maint: numeric names: authors list (
293:: CS1 maint: numeric names: authors list (
21:International Studies of Infarct Survival
193:
441:
392:
343:
286:
470:Clinical trials related to cardiology
176:Thrombolysis In Myocardial Infarction
117:to each other, and also compared the
7:
203:Journal of Interventional Cardiology
215:10.1111/j.1540-8183.1998.tb00089.x
14:
182:Myocardial infarction management
140:placebo-controlled trial of the
16:Studies of heart attack survival
101:trial that compared the three
1:
429:10.1016/S0140-6736(95)90865-X
323:10.1016/S0140-6736(88)92833-4
274:10.1016/S0140-6736(86)91607-7
229:Encyclopedia of Biostatistics
142:angiotensin-converting enzyme
380:10.1016/0140-6736(92)91893-D
111:tissue plasminogen activator
77:placebo-controlled trial of
29:randomized controlled trials
237:10.1002/0470011815.b2a01031
491:
475:Interventional cardiology
56:placebo-controlled trial
35:for treating suspected
154:isosorbide mononitrate
40:myocardial infarction
158:magnesium sulphate
423:(8951): 669–682,
374:(8796): 753–770,
317:(8607): 349–360,
482:
454:
453:
447:
439:
411:
405:
404:
398:
390:
362:
356:
355:
349:
341:
305:
299:
298:
292:
284:
257:
251:
250:
224:
218:
217:
198:
490:
489:
485:
484:
483:
481:
480:
479:
460:
459:
458:
457:
440:
413:
412:
408:
391:
364:
363:
359:
342:
307:
306:
302:
285:
268:(8498): 57–66,
259:
258:
254:
247:
226:
225:
221:
200:
199:
195:
190:
166:
134:
95:
71:
52:
17:
12:
11:
5:
488:
486:
478:
477:
472:
462:
461:
456:
455:
406:
357:
300:
252:
245:
219:
192:
191:
189:
186:
185:
184:
179:
173:
165:
162:
133:
130:
94:
91:
70:
67:
51:
48:
15:
13:
10:
9:
6:
4:
3:
2:
487:
476:
473:
471:
468:
467:
465:
451:
445:
438:
434:
430:
426:
422:
418:
410:
407:
402:
396:
389:
385:
381:
377:
373:
369:
361:
358:
353:
347:
340:
336:
332:
328:
324:
320:
316:
312:
304:
301:
296:
290:
283:
279:
275:
271:
267:
263:
256:
253:
248:
242:
238:
234:
230:
223:
220:
216:
212:
208:
204:
197:
194:
187:
183:
180:
177:
174:
171:
168:
167:
163:
161:
159:
155:
151:
147:
146:ACE inhibitor
143:
139:
131:
129:
127:
123:
120:
119:anticoagulant
116:
112:
108:
107:streptokinase
104:
100:
92:
90:
88:
87:streptokinase
84:
80:
76:
68:
66:
64:
61:
57:
49:
47:
45:
41:
38:
34:
30:
26:
22:
420:
416:
409:
371:
367:
360:
314:
310:
303:
265:
261:
255:
228:
222:
206:
202:
196:
135:
115:anistreplase
103:thrombolytic
96:
83:thrombolytic
72:
60:beta-blocker
53:
27:) were four
24:
20:
18:
144:inhibitor (
46:, England.
31:of several
464:Categories
417:The Lancet
368:The Lancet
311:The Lancet
262:The Lancet
246:047084907X
188:References
113:(tPA) and
150:captopril
138:factorial
99:factorial
75:factorial
444:citation
437:33961715
395:citation
346:citation
339:21071664
289:citation
164:See also
81:and the
63:atenolol
331:2899772
209:: 1–7,
126:aspirin
122:heparin
79:aspirin
58:of the
435:
388:560345
386:
337:
329:
282:708900
280:
243:
178:(TIMI)
132:ISIS-4
105:drugs
93:ISIS-3
69:ISIS-2
50:ISIS-1
44:Oxford
433:S2CID
384:S2CID
335:S2CID
278:S2CID
170:GISSI
156:and
85:drug
37:acute
33:drugs
450:link
401:link
352:link
327:PMID
295:link
241:ISBN
25:ISIS
19:The
425:doi
421:345
376:doi
372:339
319:doi
315:332
270:doi
266:328
233:doi
211:doi
466::
446:}}
442:{{
431:,
419:,
397:}}
393:{{
382:,
370:,
348:}}
344:{{
333:,
325:,
313:,
291:}}
287:{{
276:,
264:,
239:.
231:.
207:11
205:,
152:,
148:)
109:,
452:)
427::
403:)
378::
354:)
321::
297:)
272::
249:.
235::
213::
23:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.